ProPhase Labs, Inc.
(NASDAQ: PRPH) (www.ProPhaseLabs.com) announced today that it has
rejected the revised and unsolicited, non-binding proposal from
Matrixx Initiatives, Inc. ("Matrixx") to acquire the Company for
$1.60 per share in cash. This...
Matrixx Initiatives today announced that it has filed a presentation with the Securities and Exchange Commission ("SEC") in connection with its revised offer to acquire ProPhase Labs, Inc. (NASDAQ: PRPH). Separately today, Matrixx announced it...
ProPhase Labs (NASDAQ: PRPH) announced today that it
previously received an unsolicited, non-binding proposal from Matrixx
Initiatives, Inc. ("Matrixx") to acquire the Company for $1.40 per
share in cash, subject to further due diligence by...
HOUSTON, TX -- (Marketwire) -- 04/04/11 -- Matrixx Resource Holdings, Inc. (PINKSHEETS: MXXH), has been invited to profile the Company's progress and outlook with Mick Bazsuly on "Your Monies Worth" radio show. Due to the rising prices and an
Biotech companies have one more potential legal liability to consider as they push a new drug to the marketplace. The U.S. Supreme Court has ruled that a failure to report relevant instances of adverse events among patients is legitimate fodder...
The U.S. Supreme Court has ruled against Matrixx Initiatives, allowing a class-action lawsuit by investors to go forward after the company failed to disclose initial reports of consumers who experienced adverse side effects. Report
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.